Harvard BioscienceFRA:HBI0 48 FCF Yield % is 4.55 as of Jul. 04, 2026, which is 46% above its 10-year median of 3.12. GuruFocus rates FRA:HBI0 with a GF Score™ of 48/100 and a GF Value™ of €12.69. The stock has 7 warning signs investors should review. Among 857 Medical Devices & Instruments companies, Harvard Bioscience ranks better than 78.88% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
The historical rank and industry rank for Harvard Bioscience's FCF Yield % or its related term are showing as below:
FRA:HBI0'
s FCF Yield % Range Over the Past 10 Years
Min: -6.84 Med: 3.12 Max: 40.35
Current: 4.55
During the past 13 years, the highest FCF Yield % of Harvard Bioscience was 40.35%. The lowest was -6.84%. And the median was 3.12%.
FRA:HBI0's FCF Yield % is ranked better than 78.88% of 857
companies
in the Medical Devices & Instruments industry
Industry Median: -0.4
vs FRA:HBI0: 4.55
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Harvard Bioscience FCF Yield % Related Terms
Harvard Bioscience FCF Yield % Historical Data
* Premium members only.
The historical data trend for Harvard Bioscience's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:HBI0 vs RGNT, MLSS, RVP: FCF Yield % Comparison
For the Medical Instruments & Supplies subindustry, Harvard Bioscience's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Harvard Bioscience FCF Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Harvard Bioscience's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Harvard Bioscience's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Harvard Bioscience (FRA:HBI0) has a FCF Yield % of 4.55 as of Jul. 04, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Harvard Bioscience and its competitors. This is 46% above median its historical median of 3.12. According to the industry distribution chart, Harvard Bioscience ranks #181 out of 857 companies in the Medical Devices & Instruments industry, placing it in the top 21.1%.
Is Harvard Bioscience's FCF Yield % too high?
Harvard Bioscience's current FCF Yield % of 4.55 is 46% above median its 10-year median of 3.12. Based on the distribution chart, Harvard Bioscience ranks #181 out of 857 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Harvard Bioscience has a GF Score™ of 48/100, reflecting its overall financial health beyond just this single metric.
How does Harvard Bioscience's FCF Yield % compare to RGNT and MLSS?
According to the Medical Devices & Instruments industry distribution chart, Harvard Bioscience ranks #181 out of 857 companies for FCF Yield %. This places Harvard Bioscience in the top 21% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Medical Devices & Instruments company?
A good FCF Yield % depends on the Medical Devices & Instruments industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Harvard Bioscience and its competitors. Harvard Bioscience's current FCF Yield % is 4.55, which is 46% above median its own 10-year median of 3.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Harvard Bioscience stock overvalued right now?
Harvard Bioscience (FRA:HBI0) has a current FCF Yield % of 4.55. The stock's GF Value™ is €12.69, compared to a current price of €4.08 — trading 67.8% below its estimated fair value. The current FCF Yield % is 4.55, which is 46% above median its 10-year median of 3.12. Harvard Bioscience's overall GF Score™ is 48/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Harvard Bioscience (FRA:HBI0), the current FCF Yield % is 4.55 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Harvard Bioscience (FRA:HBI0) Overvalued in 2026?
Based on GuruFocus' analysis, Harvard Bioscience stock appears to be undervalued.
The current stock price of €4.08 is trading 67.8% below its estimated GF Value™ of €12.69.
Key valuation signals for FRA:HBI0:
FCF Yield %: 4.55 (46% above median its 10-year median of 3.12)
GF Value™: €12.69 vs. price of €4.08 (67.8% below fair value)
No single metric tells the full story. See the FRA:HBI0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, products, and services that enable advances in life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing. The company organizes its product line into two product families: Cellular and Molecular Technologies (CMT) and Preclinical. The CMT product family supports molecular, cellular, organ, and organoid research, as well as bioproduction and in vitro testing, while the Preclinical product family provides products for preclinical research and testing, including data collection and analysis for safety and regulatory compliance. Its geographical segments include the Americas, Europe, Middle East and Africa, and Asia.
48GF Score
Get the complete analysis for FRA:HBI0
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:HBI0 has been successfully added to your 
